On November 11, whale positions on Hyperliquid totaled $6.055 billion, with short positions making up 54.19% ($3.282 billion) and long positions 45.81% ($2.774 billion). This results in a net short exposure of about $508 million. The long-to-short ratio was 0.85, with longs showing a loss of $156 million and shorts a profit of $248 million. Notably, one wallet held a significant five-times cross-margin short in Bitcoin with $6.5 million unrealized profit. Compared to an earlier snapshot on October 23, total whale positions have decreased from $8.251 billion, indicating a shift in market dynamics among large traders.
The story on Hyperliquid whale positions shows a net short exposure of about $508 million as of November 11, 2026. For readers following the broader cryptocurrency market, here is Pluang's market snapshot as of Nov 12, 2026 05:22 WIB: out of 50 major cryptocurrencies, 27 rose and 22 fell today. Notable movers include CRV at Rp4.426 with a 1-day change of -2.23% and 100% buy order activity, FTM at Rp11.382 with a -2.05% change, and DOT at Rp15.441 with a +1.95% change and 77% buy order activity.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
